Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1)
in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma
(CSCC), or unresectable locally advanced CSCC that is not amenable to surgery and/or
radiation.